SERMORELIN

Growth Hormone SecretionPrimarily Compoundable

Despite decades of clinical use, the published research is surprisingly thin—mostly detection studies rather than efficacy trials. The safety track record through compounding pharmacies is solid, but the evidence base lags behind its widespread use.

Age management clinicians and researchers studying adult growth hormone deficiency rely heavily on this peptide, along with anti-aging researchers investigating natural approaches to declining GH levels.

FDA Status

Compounding Allowed

Since Feb 2026

Evidence

Limited data

Studies

14 total, 1 human

Popularity

#15 most researched

What is SERMORELIN?

As one of the first synthetic growth hormone-releasing hormones developed, this 29-amino acid peptide has earned a reputation as the 'gold standard' among GHRH analogs. Compounding pharmacies have been formulating sermorelin for over two decades, making it the most accessible growth hormone secretagogue for researchers studying natural GH stimulation. Its consistent availability and established safety profile have made it a go-to choice for clinicians exploring growth hormone deficiency treatments.

This synthetic version of the first 29 amino acids of natural GHRH binds to specific receptors on pituitary somatotroph cells, triggering the release of stored growth hormone in natural pulses. Unlike direct GH injection, sermorelin works with your body's existing regulatory systems—if your pituitary is already producing adequate GH, sermorelin won't force additional release. Think of it as pressing the 'release' button on growth hormone that's already there, rather than flooding the system with external hormones.

What the Research Shows

The 14 studies include just one human trial, with most research focused on developing laboratory detection methods rather than measuring clinical outcomes.

The evidence base for sermorelin consists of 5 human studies with no randomized controlled trials, primarily focused on analytical detection methods and clinical perspectives rather than efficacy outcomes. Key findings include development of LC-MS/MS detection methods achieving sensitivity at or below 1 ng/mL in urine and capillary electrophoresis methods detecting sermorelin analogs at 75-200 ng/mL, along with a clinical perspective on its use for adult-onset growth hormone insufficiency management.